The Clinical Center’s Blood Glucose Management Service

December 2011 in “ The Diabetes Educator ”

Kathryn Feigenbaum, Pamela G. Brooks, Christine Chamberlain, Elaine Cochran, Allison Adams-McLean, Rana Malek, David M. Harlan

exenatide hypoglycemia immunogenicity hypersensitivity reactions macrovascular outcomes adverse reactions drug interactions Pregnancy Category C renal function BYDUREON

TLDR The Blood Glucose Management Service improved patient safety and outcomes in managing blood sugar in hospitalized patients.

The document from 2011 describes the establishment and operation of the Blood Glucose Management Service (BGMS) at the NIH Clinical Center, which aimed to improve the management of blood glucose levels in hospitalized patients through a multidisciplinary team approach. The BGMS team, consisting of nurses, a nurse practitioner, a dietitian, a pharmacist, and endocrinology fellows, took full responsibility for blood glucose-related issues in referred inpatients. They met daily to review patient data and develop care plans, utilizing an electronic flow sheet for efficiency. The service was well-received, led to improved safety and patient outcomes, and reduced medication errors from 0.054 to 0.024 per patient day between 2007 and 2009. Additionally, the document provides details on the use of BYDUREON (exenatide) for diabetes treatment, including its immunogenicity, hypersensitivity reactions, macrovascular outcomes, adverse reactions, hypoglycemia, and drug interactions. It also discusses the categorization of BYDUREON as Pregnancy Category C and advises caution in its use among pregnant women, nursing mothers, pediatric and geriatric patients, and those with decreased renal function.

View this study on journals.sagepub.com →

Discuss this study in the Community →

Similar Research

5 / 37 results

A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

research A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

61 citations, January 2015 in “Hormones”

Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.

research Pharmacodynamic Evaluation: Endocrinology

January 2017

The conclusion is that endocrinology significantly impacts medicine with various common medications used for treatment.

research The Polycystic Ovary Syndrome: A Position Statement from the European Society of Endocrinology

467 citations, October 2014 in “European Journal of Endocrinology”

The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.

Short-Term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin

research Short-Term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin

116 citations, December 2013 in “European journal of endocrinology”

Combining liraglutide and metformin helps obese women with PCOS who didn't lose weight on metformin alone to lose more weight.

research An Updated Overview of Polycystic Ovary Syndrome

1 citations, June 2019 in “Innovare journal of medical sciences”

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder in women that can cause infertility and other health issues, and it may be improved by treatments that increase insulin sensitivity.